Clinical Pipeline

Below is our pipeline of investigational compounds that are currently in various stages of clinical development.

Phase 1Phase 2Phase 3

Guadecitabine (SGI-110)

DNMT inhibitor (Hematological Malignancies and Solid Tumors)

...

Guadecitabine (SGI-110)

DNMT inhibitor (Relapsed/Refractory AML)

...

Guadecitabine (SGI-110)

DNMT inhibitor (Relapsed/Refractory MDS or CMML)

...

Guadecitabine (SGI-110)

DNMT inhibitor (Solid Tumors)

. .

Decitabine and Cedazuridine (ASTX727)

Oral DNMT inhibitor (Hematological Malignancies)

...

Tolinapant (ASTX660)

Antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP) (Solid Tumors & Lymphomas)

..

ASTX029

Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)

.

ASTX295

Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)

.

Azacitidine and Cedazuridine (ASTX030)

Oral DNMT inhibitor (Hematological Malignancies)

.

TAS1440

Oral LSD1 inhibitor (Hematological Malignancies)

.

TAS1553

Oral ribonucleotide reductase (RNR) inhibitor (Hematological Malignancies)

.